Jennifer VanOudenhove, PhD
Associate Research ScientistCards
About
Research
Publications
Featured Publications
Cell Marker Accordion: interpretable single-cell and spatial omics annotation in health and disease
Busarello E, Biancon G, Cimignolo I, Lauria F, Ibnat Z, Ramirez C, Tomè G, Ciuffreda M, Bucciarelli G, Pilli A, Marino S, Bontempi V, Ress F, Aass K, VanOudenhove J, Tiberi L, Mione M, Standal T, Macchi P, Viero G, Halene S, Tebaldi T. Cell Marker Accordion: interpretable single-cell and spatial omics annotation in health and disease. Nature Communications 2025, 16: 5399. PMID: 40623970, PMCID: PMC12234662, DOI: 10.1038/s41467-025-60900-4.Peer-Reviewed Original ResearchConceptsSingle-cellBiological interpretationCell typesSingle-cell technologiesIdentification of cell typesMultiple single-cellPhysiological cell typesSingle-cell populationsCellular heterogeneityDisease contextsInconsistent annotationsMurine tissuesWeight markersAnnotationCellsSpatial populationAnnotation accuracyPathological processesAvailable databasesMarkersPotential biomarkersAutomatic annotationPhysiologyUnique opportunityDiseaseImpact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
VanOudenhove J, Liu Y, Nelakanti R, Kim D, Busarello E, Ovalle N, Qi Z, Mamillapalli P, Siddon A, Bai Z, Axtmayer A, Corso C, Kothari S, Foss F, Isufi I, Tebaldi T, Gowda L, Fan R, Seropian S, Halene S. Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant. PLOS ONE 2025, 20: e0320744. PMID: 40294012, PMCID: PMC12036906, DOI: 10.1371/journal.pone.0320744.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationMemory T cellsStem cell transplantationCell transplantationT cellsSARS-CoV-2Hematopoietic stem cell transplant recipientsAntigen-specific T-cell activationSARS-CoV-2 mRNA vaccinesSARS-CoV-2 vaccine responsesSevere diseaseAnti-spike IgGT cell activationAdaptive immune responsesRobust antibody responsesPost-vaccination responseSARS-CoV-2 infectionMRNA vaccine seriesSingle-cell RNAMyeloablative chemotherapyCellular responsesImmune profileVaccine responseCOVID-19 infectionMRNA vaccinesAplastic anemia in association with multiple myeloma: clinical and pathophysiological insights
Muradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, 65: 2182-2189. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.Peer-Reviewed Original ResearchAplastic anemiaMultiple myelomaImmunosuppressive therapyTransfusion requirementsProgenitor cellsPlasma cell-directed therapyT-cell destructionCell-directed therapiesInhibition of erythroid colony formationErythroid colony formationLevels of IL8Severe AAImmune cytopeniasPartial responseMM patientsHematopoietic stemSerum testsPartial improvementPathophysiological insightsPatientsImmune systemPlatelet apoptosisCytopeniasColony formationMyeloma
2025
Clonal Hematopoiesis Risk Score (CHRS) Evaluation as a Prognostic Marker for Death in Cardio-Oncology Cohort
Singh J, Chehayeb R, Im Y, Yi I, El Zarif T, Guajardo A, VanOudenhove J, Halene S, Jha A, Kwan J. Clonal Hematopoiesis Risk Score (CHRS) Evaluation as a Prognostic Marker for Death in Cardio-Oncology Cohort. JACC Advances 2025, 4: 102290. PMID: 41205546, DOI: 10.1016/j.jacadv.2025.102290.Peer-Reviewed Original ResearchTarget antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin
Albano F, Browning S, Li F, Bar N, Parker T, Anderson T, Stevens E, VanOudenhove J, Matthews M, Gorshein E, Haldas J, Talsania A, Sabbath K, Seropian S, Halene S, Perna F, Neparidze N. Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin. Blood 2025, 146: 7578. DOI: 10.1182/blood-2025-7578.Peer-Reviewed Original ResearchBCMA-targeted therapyBelantamab mafodotinPhase I partRelapsed/refractory myelomaClinical responseStable diseasePartial responseCombination therapyMedian ageMultiple myelomaImmune profileT cellsBone marrowB cellsDay 1PD1+ T cellsAssociated with clinical responseMedian age of patientsCD19+ B cellsFlow cytometryI partCombination of elotuzumabImmune combination therapyInferior clinical responsePhase Ib/II trial5-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients
Zhang X, Tang M, Li G, Bernardicius D, VanOudenhove J, DeZern A, Ghiaur G, Halene S, Salomonis N, Grimes H. 5-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients. Blood 2025, 146: 2054-2054. DOI: 10.1182/blood-2025-2054.Peer-Reviewed Original ResearchSingle-cell genotypingMyelodysplastic syndromeSplicing patternsPacBio long-read sequencingEctopic expressionCritical regulatorsAZA treatmentRegulation of cell survivalLong-read sequencingSecondary AMLGene programAberrant upregulationLeukemic transformationClonal stabilityCellular hallmarksMDS HSPCsPathway gene expressionCell proliferation genesCytokine Signaling PathwaysCD34+ hematopoietic stemMDS managementMolecular divergenceMyelodysplastic syndrome patientsCell activation markersDownregulation of Bcl2MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy
Bhardwaj P, Baassiri A, Sundaram R, Friedman S, Elia J, Kiwan A, Matthews M, VanOudenhove J, Mendez L, Gueble S, Bindra R, Halene S. MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy. Blood 2025, 146: 322-322. DOI: 10.1182/blood-2025-322.Peer-Reviewed Original ResearchAbstract Acute myeloid leukemiaCell-derived xenograftsCD34+ cellsAcute myeloid leukemiaMGMT silencingComplete remissionTemozolomide resistanceCDX modelsAML samplesResistance mechanisms to TMZHuman CD45+Potential of temozolomideProtein expressionTherapeutically challenging malignanciesMGMT protein expressionO6-methylguanine-DNA methyltransferaseTumor-free survivalStandard chemotherapy regimensMGMT promoter methylationPatient-derived xenograftsCell linesDNA damage responseLow-grade gliomasEpigenetic silencingAlkylating agentsExamining the role of U2AF1 and TET2 mutations in a myeloid malignancy mouse model
Cheng M, Kenworthy C, Paul S, Maul-Newby H, VanOudenhove J, Busarello E, Vigorelli M, Tebaldi T, Halene S, Biancon G. Examining the role of U2AF1 and TET2 mutations in a myeloid malignancy mouse model. Blood 2025, 146: 3837-3837. DOI: 10.1182/blood-2025-3837.Peer-Reviewed Original ResearchLineage-negative cellsComplete blood countMouse modelBone marrowSplicing factorsDM miceU2AF1 mutationsMyeloid malignanciesTET2 mutationsPeripheral bloodMutant cellsCo-mutationsAssociated with poor clinical outcomesStem cell levelHematopoietic stem cellsProgression to AMLInitiation of oncogenesisPoor clinical outcomesTerminal myeloid differentiationWild-typeDM conditionsMalignancy in vivoMutations in vivoEarly consequencesSplicing factor mutationsMETTL3 inhibition disrupts R-loop homeostasis and activates the cgas-sting pathway in Acute Myeloid Leukemia
Yang H, VanOudenhove J, Wei M, Ramirez C, Maul-Newby H, Fedorov E, Conway C, King M, Tothova Z, Ofir-Rosenfeld Y, Tebaldi T, Halene S. METTL3 inhibition disrupts R-loop homeostasis and activates the cgas-sting pathway in Acute Myeloid Leukemia. Blood 2025, 146: 5061-5061. DOI: 10.1182/blood-2025-5061.Peer-Reviewed Original ResearchDNA-RNA hybridsDNA double-strand breaksGene Set Enrichment AnalysisR-loopsDNA-RNA immunoprecipitationR-loop accumulationYT521-B homologyDown-regulated genesInnate immune responseDNA-RNAAbstract Acute myeloid leukemiaProximity ligation assayCGAS-STING pathwayMOLM13 cellsResolution of R-loopsNuclear export factor CRM1Accumulation of R-loopsR-loop homeostasisR-loop formationExport factor CRM1R-loop dynamicsRNA-seq dataAntiviral innate immune responseCatalytically dead formInsulin-like growth factor 2 mRNA-binding proteins2003 – MOLECULAR DISSECTION OF AGING CLARIFIES THE IMPACT OF MDS GENETICS AND THERAPY
Grimes H, Zhang X, Tang M, Li G, Bernardicius D, Van Oudenhove J, DeZern A, Ghiaur G, Halene S, Salomonis N. 2003 – MOLECULAR DISSECTION OF AGING CLARIFIES THE IMPACT OF MDS GENETICS AND THERAPY. Experimental Hematology 2025, 151: 104916. DOI: 10.1016/j.exphem.2025.104916.Peer-Reviewed Original ResearchHematopoietic stem cellsSecondary acute myeloid leukemiaMyelodysplastic syndromeHematopoietic stem/progenitor cellsHypomethylating agentsMegakaryocyte-erythroid progenitorsMouse model of myelodysplastic syndromesModel of myelodysplastic syndromeMouse modelHypomethylating agent therapyRegulation of cell survivalMyelodysplastic syndrome progressionAcute myeloid leukemiaCellular hallmarksAssociated with downregulationImpact of myelodysplastic syndromesPathway gene expressionSerial bone biopsiesAged marrowDiagnostic biopsyClinical responseClonal hematopoiesisBioinformatics toolkitTherapy resistanceLeukemic transformation
News
Get In Touch
Contacts
Mailing Address
Yale University
300 George St, Rm 787A
New Haven, CT 06511
United States